Literature DB >> 24113843

The role of secretory phospholipase A₂ in the central nervous system and neurological diseases.

Tatsurou Yagami1, Yasuhiro Yamamoto, Hiromi Koma.   

Abstract

Secretory phospholipase A2 (sPLA2s) are small secreted proteins (14-18 kDa) and require submillimolar levels of Ca(2+) for liberating arachidonic acid from cell membrane lipids. In addition to the enzymatic function, sPLA2 can exert various biological responses by binding to specific receptors. Physiologically, sPLA2s play important roles on the neurotransmission in the central nervous system and the neuritogenesis in the peripheral nervous system. Pathologically, sPLA2s are involved in the neurodegenerative diseases (e.g., Alzheimer's disease) and cerebrovascular diseases (e.g., stoke). The common pathology (e.g., neuronal apoptosis) of Alzheimer's disease and stroke coexists in the mixed dementia, suggesting common pathogenic mechanisms of the two neurological diseases. Among mammalian sPLA2s, sPLA2-IB and sPLA2-IIA induce neuronal apoptosis in rat cortical neurons. The excess influx of calcium into neurons via L-type voltage-dependent Ca(2+) channels mediates the two sPLA2-induced apoptosis. The elevated concentration of intracellular calcium activates PKC, MAPK and cytosolic PLA2. Moreover, it is linked with the production of reactive oxygen species and apoptosis through activation of the superoxide producing enzyme NADPH oxidase. NADPH oxidase is involved in the neurotoxicity of amyloid β peptide, which impairs synaptic plasticity long before its deposition in the form of amyloid plaques of Alzheimer's disease. In turn, reactive oxygen species from NADPH oxidase can stimulate ERK1/2 phosphorylation and activation of cPLA2 and result in a release of arachidonic acid. sPLA2 is up-regulated in both Alzheimer's disease and cerebrovascular disease, suggesting the involvement of sPLA2 in the common pathogenic mechanisms of the two diseases. Thus, our review presents evidences for pathophysiological roles of sPLA2 in the central nervous system and neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24113843     DOI: 10.1007/s12035-013-8565-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  107 in total

1.  Cloning and recombinant expression of a novel mouse-secreted phospholipase A2.

Authors:  E Valentin; R S Koduri; J C Scimeca; G Carle; M H Gelb; M Lazdunski; G Lambeau
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

Review 2.  Vascular dementia. Stroke risk and sequelae define therapeutic approaches.

Authors:  Sandra E Black
Journal:  Postgrad Med       Date:  2005-01       Impact factor: 3.840

3.  Novel human secreted phospholipase A(2) with homology to the group III bee venom enzyme.

Authors:  E Valentin; F Ghomashchi; M H Gelb; M Lazdunski; G Lambeau
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

4.  Modulation of DL-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)/quisqualate receptors by phospholipase A2 treatment.

Authors:  G Massicotte; M Baudry
Journal:  Neurosci Lett       Date:  1990-10-16       Impact factor: 3.046

5.  Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals.

Authors:  K Ueda; S Shinohara; T Yagami; K Asakura; K Kawasaki
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

6.  Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain.

Authors:  Teng-Nan Lin; Qun Wang; Agnes Simonyi; Jean-Ju Chen; Wai-Mui Cheung; Yong Y He; Jan Xu; Albert Y Sun; Chung Y Hsu; Grace Y Sun
Journal:  J Neurochem       Date:  2004-08       Impact factor: 5.372

7.  Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation.

Authors:  Florence Pinto; Talma Brenner; Phyllis Dan; Miron Krimsky; Saul Yedgar
Journal:  Glia       Date:  2003-12       Impact factor: 7.452

8.  Association between BanI genotype and increased phospholipase A2 activity in schizophrenia.

Authors:  Nadia R Barbosa; Ricardo M Junqueira; Homero P Vallada; Wagner F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270

9.  Membrane lipid degradation is related to interictal cortical activity in a series of seizures.

Authors:  F Visioli; E B Rodriguez de Turco; N R Kreisman; N G Bazan
Journal:  Metab Brain Dis       Date:  1994-06       Impact factor: 3.584

10.  Human group III secreted phospholipase A2 promotes neuronal outgrowth and survival.

Authors:  Seiko Masuda; Kei Yamamoto; Tetsuya Hirabayashi; Yukio Ishikawa; Toshiharu Ishii; Ichiro Kudo; Makoto Murakami
Journal:  Biochem J       Date:  2008-01-15       Impact factor: 3.857

View more
  18 in total

Review 1.  Therapies targeting lipid peroxidation in traumatic brain injury.

Authors:  Tamil Selvan Anthonymuthu; Elizabeth Megan Kenny; Hülya Bayır
Journal:  Brain Res       Date:  2016-02-10       Impact factor: 3.252

2.  Astrocytes regulate α-secretase-cleaved soluble amyloid precursor protein secretion in neuronal cells: Involvement of group IIA secretory phospholipase A2.

Authors:  X Yang; W Sheng; D M Ridgley; M A Haidekker; G Y Sun; J C Lee
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

Review 3.  Common mechanisms of Alzheimer's disease and ischemic stroke: the role of protein kinase C in the progression of age-related neurodegeneration.

Authors:  Brandon P Lucke-Wold; Ryan C Turner; Aric F Logsdon; James W Simpkins; Daniel L Alkon; Kelly E Smith; Yi-Wen Chen; Zhenjun Tan; Jason D Huber; Charles L Rosen
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

4.  NGF induces the expression of group IIA secretory phospholipase A2 in PC12 cells: the newly synthesized enzyme is addressed to growing neurites.

Authors:  Vincenza Nardicchi; Monica Ferrini; Francesca Pilolli; Emanuela Biagioni Angeli; Emanuele Persichetti; Tommaso Beccari; Roberta Mannucci; Cataldo Arcuri; Rosario Donato; Robert V Dorman; Gianfrancesco Goracci
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

Review 5.  Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.

Authors:  Tatsurou Yagami; Hiromi Koma; Yasuhiro Yamamoto
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

6.  DSePA Antagonizes High Glucose-Induced Neurotoxicity: Evidences for DNA Damage-Mediated p53 Phosphorylation and MAPKs and AKT Pathways.

Authors:  Kun Wang; Xiao-Yan Fu; Xiao-Ting Fu; Ya-Jun Hou; Jie Fang; Shuai Zhang; Ming-Feng Yang; Da-Wei Li; Lei-Lei Mao; Jing-Yi Sun; Hui Yuan; Xiao-Yi Yang; Cun-Dong Fan; Zong-Yong Zhang; Bao-Liang Sun
Journal:  Mol Neurobiol       Date:  2015-08-01       Impact factor: 5.590

Review 7.  Alcohol, phospholipase A2-associated neuroinflammation, and ω3 docosahexaenoic acid protection.

Authors:  Michael A Collins; Nuzhath Tajuddin; Kwan-Hoon Moon; Hee-Yong Kim; Kimberly Nixon; Edward J Neafsey
Journal:  Mol Neurobiol       Date:  2014-04-06       Impact factor: 5.590

8.  Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition.

Authors:  Meiling Tang; Lu Jiang; Yingying Lin; Xiaoli Wu; Kai Wang; Qizhi He; Xipeng Wang; Weiping Li
Journal:  Oncotarget       Date:  2017-10-27

9.  Large-scale interaction effects reveal missing heritability in schizophrenia, bipolar disorder and posttraumatic stress disorder.

Authors:  H J Woo; C Yu; K Kumar; J Reifman
Journal:  Transl Psychiatry       Date:  2017-04-11       Impact factor: 6.222

Review 10.  Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders.

Authors:  Kunio Yui; George Imataka; Hiroyuki Nakamura; Naoki Ohara; Yukiko Naito
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.